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Introduction
Primary graft dysfunction (PGD), a form of  acute lung injury after lung transplantation (LTx) (1, 2), 
occurs in 25%–30% of  patients after lung transplant. This complication leads to an increased duration 
of  mechanical ventilation and hospitalization and an increased risk of  bronchiolitis obliterans syndrome 
BACKGROUND. The complement system plays a key role in host defense but is activated by 
ischemia/reperfusion injury (IRI). Primary graft dysfunction (PGD) is a form of acute lung injury 
occurring predominantly due to IRI, which worsens survival after lung transplantation (LTx). Local 
complement activation is associated with acute lung injury, but whether it is more reflective 
of allograft injury compared with systemic activation remains unclear. We proposed that local 
complement activation would help identify those who develop PGD after LTx. We also aimed to 
identify which complement activation pathways are associated with PGD.
METHODS. We performed a multicenter cohort study at the University of Pennsylvania and 
Washington University School of Medicine. Bronchoalveolar lavage (BAL) and plasma specimens 
were obtained from recipients within 24 hours after LTx. PGD was scored based on the consensus 
definition. Complement activation products and components of each arm of the complement 
cascade were measured using ELISA.
RESULTS. In both cohorts, sC4d and sC5b-9 levels were increased in BAL of subjects with PGD 
compared with those without PGD. Subjects with PGD also had higher C1q, C2, C4, and C4b, 
compared with subjects without PGD, suggesting classical and lectin pathway involvement. Ba 
levels were higher in subjects with PGD, suggesting alternative pathway activation. Among lectin 
pathway–specific components, MBL and FCN-3 had a moderate-to-strong correlation with the 
terminal complement complex in the BAL but not in the plasma.
CONCLUSION. Complement activation fragments are detected in the BAL within 24 hours after 
LTx. Components of all 3 pathways are locally increased in subjects with PGD. Our findings create a 
precedent for investigating complement-targeted therapeutics to mitigate PGD.
FUNDING. This research was supported by the NIH, American Lung Association, Children’s 
Discovery Institute, Robert Wood Johnson Foundation, Cystic Fibrosis Foundation, Barnes-Jewish 
Hospital Foundation, Danish Heart Foundation, Danish Research Foundation of Independent 
Research, Svend Andersen Research Foundation, and Novo Nordisk Research Foundation.
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(3, 4). Although the mechanisms driving the development of  PGD are not completely understood, isch-
emia/reperfusion injury (IRI) has been identified as the predominant inciting etiology (5, 6).
IRI initiates PGD by engaging pathways associated with inflammation and innate immune activation 
(6–9). We previously demonstrated that elevated plasma levels of  the innate immune protein long pentrax-
in-3 (PTX3), produced by macrophages, dendritic cells, and endothelial cells, were associated with PGD in 
patients with idiopathic pulmonary fibrosis (10). Furthermore, we identified an association between PTX3 
single nucleotide polymorphisms and PGD after LTx (11). PTX3 release leads to activation of  the comple-
ment cascade, which drives an amplification loop of  innate immunity that exacerbates inflammation (12, 13). 
However, whether this activation occurs within the lung or peripherally is currently unknown.
The complement cascade can be activated via 3 distinct pathways: classical, lectin, and alternative 
(14). The classical pathway is engaged by antigen-antibody complexes as well as by short (i.e., CRP) 
and long pentraxins (i.e., PTX3). Lectin pathway activation is mediated by surface recognition of  car-
bohydrates on pathogens and injured tissues, such as lectins, ficolins, and collectins (13). Alternative 
pathway activation constitutively occurs at low levels and is amplified when C3 and factor B engage 
in a feedback loop to deposit C3b on a target (14). Activation of  the complement system amplifies 
inflammation by generating anaphylatoxins (i.e., C3a, C5a), which increase blood vessel permeability 
and mediate leukocyte chemotaxis (14). Additionally, complement activation results in formation of  
membrane attack complexes (C5b-9) on endothelial cells, which have been implicated in acute lung 
injury (15, 16) as well as end-organ damage in different preclinical thoracic organ transplant models 
(17). We previously demonstrated that an increase in plasma C5a between 6 and 24 hours after trans-
plantation was associated with severe PGD and an increased risk of  death (18). C3d and C4d staining 
were also observed within 3 months after transplantation in lung allografts of  subjects who developed 
severe PGD (19). Moreover, in a randomized, double-blinded, multicenter trial, prereperfusion admin-
istration of  TP10 (a drug that reduced complement activation by inactivating the C3 and C5 conver-
tases) decreased the duration of  mechanical ventilation after LTx compared with placebo (20). Thus, 
complement activation appears to play an important role in PGD; however, if  markers of  complement 
activation differ in those who develop PGD versus those who do not, which pathways are engaged, 
and, importantly, whether this activation is systemic or primarily local, remain unanswered.
Here we sought to (a) assess whether markers of  complement activation are elevated in the lung and 
blood compartments early after LTx in subjects with PGD, (b) identify which pathways for complement 
activation are engaged in these subjects, and (c) determine the relationship between complement activation 
in the bronchoalveolar lavage (BAL) and that in the systemic circulation.
Results
Demographic characteristics of  the cohort. In the Penn cohort (n = 136, Table 1 and Figure 1), the incidence 
of  grade 3 PGD (Supplemental Tables 1 and 2; supplemental material available online with this article; 
https://doi.org/10.1172/jci.insight.138358DS1) between 48 and 72 hours was 27.9%, compared with that 
in the WUSM cohort (n = 80, Table 1 and Figure 1), in which it was only 6.3%. As a result, we reported 
results in those who developed any grade of  PGD in the WUSM cohort (n = 53, 66.3%) and did subgroup 
analyses in (a) those who developed any grade of  PGD at or after 24 hours (n = 44, 55%) and (b) those 
who developed grade 2 or 3 PGD at any time point (n = 29, 36.3%). The distribution of  certain key factors, 
including intraoperative extracorporeal life support (ECLS), were more similar across centers when using 
these distinct PGD definitions to compare the 2 cohorts (as shown in Table 1).
Complement activation is associated with increased PGD severity within the first 24 hours of  LTx. The accumulation 
of C4d fragments, on tissue or in the fluid phase (as soluble C4d [sC4d]), or both, is a general marker of comple-
ment activation (21). In the Penn cohort, BAL concentrations of sC4d were higher in subjects with PGD (545.01 
ng/mL) compared with subjects without PGD (243.97 ng/mL) (P = 0.005; Figure 2A and Table 2). sC4d levels 
remained higher in those with grade 2 or 3 PGD versus those with grade 0 or 1 PGD at any time point (P = 
0.0006; Supplemental Figure 1A and Table 2). Thus, we identified differences in the accumulation of C4d frag-
ments in the BAL of subjects with PGD in the Penn cohort, using 2 distinct definitions of PGD: (a) as normally 
reported in prior publications (1–4) (grade 3 in the first 48–72 hours) and (b) similar to the outcome definition 
as the WUSM cohort — grade 2 or 3 PGD at any time point. Additionally, the generation of the terminal com-
plement complex (TCC), measured using BAL sC5b-9 levels, was higher in subjects with PGD (971.5 ng/mL) 
compared with subjects without PGD (175 ng/mL) (P = 0.01; Figure 2B, Supplemental Figure 1B, and Table 2) 
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and highly correlated with concurrently measured BAL C4d levels (Spearman’s rho = 0.79, n = 77, P < 0.001). 
Both BAL sC4d and sC5b-9 levels progressively increased with the grade of PGD severity (P = 0.0075 for sC4d, 
P = 0.0723 for sC5b-9; Figure 2, C and D).
We then sought to test the results in a second independent cohort with inherent differences in PGD 
grades, lesser ECLS use, and later sampling points. Even in the WUSM cohort, median BAL concentra-
tions of  sC4d were higher in subjects with PGD (167.9 ng/mL) compared with subjects without PGD 
(68.82 ng/mL) (P = 0.011, Figure 3A and Table 2). Similar to the Penn cohort results, median sC5b-9 lev-
els were higher in subjects with PGD (13.48 ng/mL) compared with subjects without PGD (5.69 ng/mL) 
(P = 0.023, Figure 3B and Table 2). This relationship held true when PGD was restricted to that occurring 
at or after 24 hours (P = 0.054, Supplemental Figure 2A). There was a difference between subjects with 
grade 2 or 3 PGD versus those with grade 0 or 1 PGD, but this did not reach statistical significance (P = 
0.073 for sC5b-9, Supplemental Figure 2B and P = 0.052 for sC4d, Supplemental Figure 2C). Levels of  the 
central components of  the complement cascade, such as C5 and C9, were elevated in the BAL of  subjects 
with PGD, compared with that of  subjects without PGD (Supplemental Figure 3, A and B, and Table 3). 
Additionally, soluble iC3b, which is generated upon complement cascade activation from C3, was elevat-
ed in the BAL of  subjects with PGD compared with that from subjects without PGD. In particular, iC3b 
levels were higher in those subjects developing PGD (4822.53 ng/mL) compared with subjects without 
PGD (1359.67 ng/mL) (P = 0.006, Supplemental Figure 3C and Table 3). We also evaluated the iC3b/
C3 ratio as a relative measure of  complement activation; it was elevated in those subjects developing PGD 
(125.64 vs. 33.58, P = 0.009, Supplemental Figure 3D and Table 3). Finally, levels of  BAL sC5b-9 highly 
correlated with concurrently measured BAL sC4d levels (Spearman’s rho = 0.694, n = 59, P < 0.001) and 
BAL iC3b levels (Spearman’s rho = 0.523, n = 36, P = 0.001).
Given that ECLS in itself is known to increase complement activation products (22, 23), we analyzed their 
levels in subjects (from both cohorts) who received ECLS compared with those who did not. In the Penn cohort, 
the median sC4d levels were comparable (median, interquartile range [IQR, ng/mL]: 365, 201.2–624.8 in those 
who received ECLS, compared with 241.2: 111–590.1 in those who did not, P = 0.3) as were the median sC5b-9 
levels (median, IQR, ng/mL: 499, 114–1027 in those who received ECLS, compared with 294, 60–960 in those 
who did not, P = 0.5). These findings were replicated in the WUSM cohort, in which the median C4d levels were 
comparable (median, IQR, ng/mL: 112.64, 61.32–345.83, in those who received ECLS, compared with 119.73, 
67.46–261.39, in those who did not, P = 0.78), as were the median sC5b-9 levels (median, IQR, ng/mL: 6.47, 
1.19–25.53, in those who received ECLS, compared with 10.05, 1.99–25.44, in those who did not, P = 0.58).
PGD severity is associated with the classical/lectin pathways of  the complement cascade and activation of  the 
alternative pathway. We then sought to identify which pathways of  complement activation were associated 
with PGD in the WUSM cohort. To this end, we measured C1q (a component of  the classical pathway), 
mannose-binding lectin (MBL, a component of  the lectin pathway), and C2 and C4 (components common 
Figure 1. CONSORT flow diagram. CONSORT flow diagram for subjects enrolled in the study at the University of Pennsylvania and Washington University 
School of Medicine. LTx, lung transplantation; PGD, primary graft dysfunction.
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to both the classical and lectin pathways), as well as factor B and factor D (components of  the alternative 
pathway). We also measured C4b, which is cleaved from C4, pointing to classical and/or lectin pathway 
activation, and Ba, which is cleaved from factor B, indicating alternative pathway activation.
We found that the median levels of  C1q, C2, and C4 in the BAL were all elevated in subjects with 
PGD as compared with those without PGD (Figure 4, A–C, and Table 3). Additionally, median C4b levels 
were also elevated in the BAL of  those subjects with PGD (139.59 ng/mL) compared with those without 
PGD (67.49 ng/mL), suggesting activation of  both the classical and lectin pathways, not just an increase 
in their individual components (P = 0.002, Figure 4D and Table 3). Median MBL levels were also elevated 
in subjects with PGD (2.3 ng/mL) compared with subjects without PGD (1.08 ng/mL, P = 0.012 for PGD 
vs. subjects without PGD, Figure 4E and Table 3). Although we noted no differences in the absolute levels 
of  factor B among those subjects who developed PGD as compared with those who did not develop PGD 
(Supplemental Figure 4A), the median levels of  Ba were significantly elevated in these subjects (Figure 4F 
and Table 3), and the levels of  factor D demonstrated a trend toward significance (Supplemental Figure 4B 
and Table 3). Taken collectively, our findings suggest that not only are individual analytes belonging to the 
classical and lectin pathways of  the complement cascade higher among subjects with PGD, but analytes 
indicating alternative pathway activation are also elevated in these subjects.
Local markers of  lectin pathway engagement distinguish subjects with PGD. Given the considerable variability 
in MBL levels in humans (24), we first quantified MBL in the BAL using a different assay and, second, did a 
comprehensive assessment of  lectin pathway analytes in both the BAL and plasma levels in the WUSM cohort. 
Table 1. Demographics of study cohort
Penn cohort (n = 136) WUSM cohort (n = 80)
PGD (n = 38) Non-PGD (n = 98) PGD (n = 53) Non-PGD (n = 27)
Donor
Male sex, n (%) 24 (63) 51 (52) 31 (59) 17 (63)
Female sex, n (%) 14 (37) 47 (48) 22 (41) 10 (37)
Age in yr, median (IQR) 37 (15, 66) 36 (16, 72) 31 (21, 46) 32 (21, 46)
Race, n (%)
White 28 (73.7) 73 (74.5) 43 (81.1) 21 (77.8)
African American 5 (13.2) 17 (17.4) 7 (13.2) 5 (18.5)
Smoking history, yes, n (%) 25 (65.8) 57 (58.2) 32 (61.5) 14 (51.9)
Recipient
Male sex, n (%) 24 (63.2) 59 (60.2) 30 (56.6) 18 (66.7)
Female sex, n (%) 14 (36.8) 39 (39.8) 23 (43.4) 18 (33.3)
Age in yr, median (IQR) 56 (52, 60) 57 (54, 60) 59 (48,65) 59 (56,64)
BMI, median (IQR) 26.4 (24.9, 27.9) 24.9 (24.0, 25.8) 24.4 (19.8, 27.4) 26.9 (24.9, 29.8)
Diagnosis, n (%)
COPD 7 (18.4) 25 (25.5) 15 (28.3) 12 (44.4)
Interstitial lung disease 18 (47.4) 55 (56.1) 20 (37.7) 13 (48.1)
Cystic fibrosis 3 (7.9) 10 (10.2) 11 (20.8) 0 (0.0)
Other 10 (26.3) 8 (8.2) 7 (13.2) 2 (7.4)
MPAP, median (IQR) 33 (10, 92) 29 (11, 70) 30 (24, 33) 28 (24, 35)
Race, n (%)
White 31 (81.6) 88 (89.8) 23 (85.2) 53 (100)
African American 6 (15.8) 5 (5.1) 4 (14.8) 0 (0.0)
Operative 
Ischemic time, min, median (IQR) 272.8 (228.2, 317.3) 264.0 (241.3, 286.8) 293.5 (263.5, 338.8) 304.0 (229.5, 322)
Single lung transplant, n (%) 10 (26.3) 38 (38.8) 0 (0.0) 1 (3.7)
ECLS use, yes, n (%) 17 (55.3) 38 (38.8) 29 (54.7) 8 (29.6)
Units of PRBC transfused during LTx, 
median (range)
3 (0–7) 1 (0–17) 3 (0–21) 0 (0–11)
BMI, body mass index; COPD, chronic obstructive pulmonary disease; ECLS, extracorporeal life support; LTx, lung transplant; MPAP, mean pulmonary 
arterial pressure; PGD, primary graft dysfunction; PRBC, packed red blood cells; RHC, right heart catheterization. Numbers in brackets represent proportion 
of the column for categorical variables. Continuous variables are represented as median (interquartile range [IQR]), except for transfusion, where the entire 
range was provided. DNote that the definitions for PGD were different between the 2 cohorts, as described in the Methods.
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We evaluated the association of  these analytes with an independent marker of  complement activation in 
both BAL and plasma, C4c, and validated it using a separate assay for sC5b-9 distinct from what we had 
used previously (termed TCC to semantically distinguish it from the prior assay). We found that BAL MBL 
levels highly correlated with markers of  complement activation in the BAL (Spearman’s rho = 0.637 with 
TCC, Table 4 and Figure 5A, Spearman’s rho = 0.586 with C4c, Table 4 and Supplemental Figure 5A, both 
P < 0.001). Subjects with PGD had higher BAL MBL levels compared with those who did not develop 
PGD (Figure 5C and Supplemental Table 4). Additionally, in a subgroup analysis of  those subjects who 
developed PGD at or after 24 hours, BAL MBL levels remained elevated in subjects who developed PGD 
compared with those who did not develop PGD (0.667 vs. 0.00, P = 0.048, Figure 5D).
Next, we probed for different proteins that engage with the lectin pathway. Among the ficolins, we found 
that BAL ficolin-3 (FCN-3) levels at 24 hours strongly correlated with markers of  complement activation 
in the BAL (Spearman’s rho = 0.703 with TCC, Table 4 and Figure 5B, Spearman’s rho = 0.679 with C4c, 
Table 4 and Supplemental Figure 5B, both P < 0.001). Despite these differences in local complement acti-
vation products in LTx, there was minimal-to-no correlation between BAL TCC levels and plasma levels of  
TCC, C4c, or the other markers of  lectin pathway engagement, nor were there any differences in the absolute 
levels (Supplemental Tables 5 and 6). There was also no correlation between the BAL levels of  TCC and 
FCN-1 or FCN-2 (Table 4). These observations suggest that specific markers of  the lectin pathway in the 
BAL highly correlate with evidence of  local complement activation.
Given that (a) there is a known association between plasma PTX3 levels and PGD in lung transplant 
recipients (10) and (b) PTX3 is associated with activation of  both the classical/lectin pathways of  the com-
plement system (13), we further asked if  PTX3 levels were associated with either circulating or local mark-
ers of  complement activation in these subjects. In the Penn cohort, there was a modest positive correlation 
between BAL PTX3 levels with concurrently measured BAL sC4d levels (Spearman’s rho = 0.393, P < 
0.001, Figure 6A). This relationship also held true in the WUSM cohort, in which we used independent 
assays. We found a modest correlation between BAL PTX3 levels and markers of  complement activation 
Figure 2. Complement activation is associated with increased PGD severity. Levels of sC4d (A) and sC5b-9 (B) in 
subjects who developed PGD compared with those who did not. Graphs in C and D demonstrate that the values of both 
sC4d and sC5b-9 increased as the PGD severity worsened. **P < 0.01 for grade 3 PGD vs. grade 0 PGD for sC4d, *P < 
0.05 for sC5b-9; Mann-Whitney U test for A and B and Kruskal-Wallis test after adjusting for multiple comparisons 
(Dunn’s multiple comparisons test) for C and D. Penn cohort, n = 136.
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(Spearman’s rho = 0.312 with TCC, Figure 6B, Spearman’s rho = 0.386 with C4c, Figure 6C, both P < 0.05) 
in the WUSM cohort, despite there being no correlation between plasma PTX3 levels and markers of  com-
plement activation (Spearman’s rho = –0.034) within 24 hours after LTx (Supplemental Table 5). Finally, 
there were also no differences in the median values of  BAL PTX3 in subjects with PGD (15.18 ng/mL, n 
= 31) and subjects without PGD (12.99 ng/mL, n = 81) in the Penn cohort (P = 0.4, Supplemental Figure 
6). These observations suggest there are components of  the lectin pathway, other than PTX3, that better 
correlate with markers of  complement activation and distinguish those subjects with PGD.
Discussion
While the role of complement activation in acute lung injury has been evaluated in both experimental (16) and 
clinical settings (25, 26), its role in lung allograft injury is only beginning to be explored (27, 28). While targeting 
the complement cascade has been successful in certain preclinical models (29–31), follow-up studies have been 
met with tempered enthusiasm, despite moderate success in clinical trials (20, 32). This is likely due to a lack 
of data regarding (a) whether the complement cascade is actually being activated, as determined by formation 
of the membrane attack complex (vs. detecting anaphylatoxins generated by serine proteases i.e., elastase), (b) 
at what time point after LTx it is activated, and (c) if  this activation occurs in the lungs. Additionally, we do not 
know which pathways to target, given that the complement cascade can be activated via multiple routes. For 
example, C1-esterase inhibitor  — the therapeutic that has shown the most promise in human lung transplant 
recipients (32) — has multiple targets, including several that extend beyond inhibiting complement activation 
(33). Hence, given the increasing data on the role of complement activation in human LTx (18, 19), answering 
the above-mentioned questions is critical before developing targeted therapeutics for mitigating PGD.
Using 2 independent cohorts, we demonstrated that complement activation occurs primarily in the 
lungs (assessed using BAL fluid), as compared with that detected in the circulation of  subjects with 
PGD within the first 24 hours after LTx. We demonstrated the specificity of  this activation using sol-
uble C5b-9 (sC5b-9), which is reflective of  the membrane attack complex or TCC being formed due to 
complement cascade activation. We also identified complement activation using multiple independent 
markers (i.e.,iC3b, C4b, C4d). Using a panel of  analytes to differentiate components of  the classical, 
lectin, and alternative pathways, we showed that C4 (as well as C4b, indicating cleavage of  C4), C1q, 
and MBL are higher in subjects with PGD compared with those without PGD, as are Ba levels, sug-
gesting alternative pathway activation. We also detected higher levels of  C2 in the BAL of  subjects 
with PGD, and alveolar epithelial cells are a known source of  C2 production (14). These findings show 
complement activation within grafts damaged by IRI is primarily occurring through classical and/
or lectin pathway activation but likely amplified by the alternative pathway (34, 35). We also used 2 
independent measures of  MBL levels in the BAL of  LTx recipients to further validate our findings.
These findings prompt the question of  what could be activating the classical or lectin pathway in 
subjects with PGD. The classical pathway is primarily activated by immune complexes comprising 
antigens bound to specific antibodies that can fix C1q, resulting in formation of  the C1 complex (36). 
Table 2. Markers of complement activation in bronchoalveolar lavage fluid of subjects with and without 
PGD in the first 24 hours of lung transplant
Penn cohort
Non-PGD (n = 86) PGD (n = 33) PA
sC4d 243.97 (96.58–481.88) 545.01 (227.49–861.61) 0.005
sC5b-9B 175.00 (61–784.5) 971.5 (80.75–1649.5) 0.01
WUSM cohort
Non-PGD (n = 27) PGD (n = 53) PA
sC4dC 68.82 (51.96–116.59) 167.9 (82.95–369.63) 0.011
sC5b-9 5.69 (0.93–11.49) 13.48 (2.94–31.76) 0.023
Values are expressed in ng/mL as median (interquartile range). ARank sum test. BsC5b-9 measurements in the University 
of Pennsylvania (Penn) cohort were done in 56 subjects without PGD and 22 subjects with PGD. CsC4d measurements 
in the Washington University School of Medicine (WUSM) cohort were done in 14 subjects without PGD and 45 subjects 
with PGD. Note that the definitions for PGD were different between the 2 cohorts, as described in the Methods.
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Formation of  this complex activates the serine protease C1s, which can then trigger a cascade involving 
the sequential cleavage of  C4, followed by C2, then C3, and C5, eventually resulting in the formation 
of  C5b-9 on the target surface. However, C1 also binds to C-reactive protein and PTX3, among other 
acute-phase reactants (37). Moreover, different lectins bind to the surface of  carbohydrates to activate 
MBL/ficolin/collectin-associated serine proteases (MASPs), which are enzymes that can attach to sub-
strates such as MBL and facilitate C2 and C4 cleavage (38). Additionally, FCN-3, which forms a sub-
strate for binding to MASPs (39–41), was highly correlated with markers of  complement activation in 
the WUSM cohort. FCN-3 is synthesized in the liver and bile ducts but also in the lungs (42). Addition-
ally, tissue-specific recruitment of  FCN-3 to the lungs has been reported in the context of  LPS-mediated 
acute lung injury in humans (43). These observations led us to consider the possibility that increased 
airway accumulation of  these proteins after IRI may be triggering local complement cascade activation 
in the lungs via the lectin pathway.
Although PTX3 has been associated with IRI in other model systems (44) and is a known activator 
of  the complement cascade (12, 13), it has remained unclear if  its accumulation correlates with markers 
of  complement activation. Interestingly, the association of  PTX3 with markers of  complement activation 
in the BAL was modest and, unlike MBL, was not different in those subjects with and without PGD. 
Figure 3. Complement activation is associated with increased PGD severity within the first 24 hours of lung transplan-
tation. Levels of sC4d (A) and sC5b-9 (B) were elevated in subjects who developed PGD compared with those who did not. 
Note that there were inherent differences in clinical practices at the 2 centers, including the variability in the volume of fluid 
instilled into the lung, as well as the return, which partially explain the differences in the levels of sC4d and sC5b-9 when 
compared with Figure 2. Rank sum tests of comparison (Mann-Whitney U test). WUSM cohort, n = 80.
Table 3. Components of the complement cascade in bronchoalveolar lavage fluid of subjects with and 
without PGD within first 24 hours of lung transplant (WUSM)
Non-PGD (n = 27) PGD (n = 46) P A
C1qB,C 27.60 (19.55–38.34) 45.40 (32.32–67.53) 0.039
C2C 94.29 (69.24–197.95) 207.47 (96.19–401.88) 0.009
C4B,C 73.62 (44.0–99.11) 147.21 (102.07–229.41) 0.004
C4bB,C 67.49 (18.61–119.03) 139.59 (83.80–236.26) 0.002
MBLB,C 1.08 (0.56–2.33) 2.3 (1.48–9.21) 0.012
Factor B 26.3 (22.41–53.89) 45.6 (25.43–60.08) 0.371
BaC 52.86 (37.3–81.4) 73.56 (51.36–161.46) 0.024
Factor D 8.39 (5.00–16.52) 13.47 (6.79–17.30) 0.089
C3 28.79 (16.90–46.43) 39.59 (21.54–52.28) 0.265
iC3bB,C 1359.67 (497.21–2508.71) 4822.53 (2875.27–15524.85) 0.006
iC3b: C3B,C 33.58 (18.36–87.33) 125.64 (68.96–479.46) 0.009
C5 211.39 (116.97–392.8) 364.59 (169.8–624.59) 0.023
C9B,C 34.05 (34.05–46.17) 85.81 (44.15–123.29) 0.005
BL, mannose-binding lectin. Values are expressed in ng/mL as median (interquartile range). Components of kit 2 
(C1q, C4, factor B, iC3b, C3, and C9) were measured in a subset of subjects with PGD (n = 27) and without PGD (n = 9). 
ARank sum test. BP < 0.05 even when PGD was redefined as occurring at or after 24 hours (non-PGD [n = 35], PGD [n = 38]). 
CP < 0.05 even when PGD was restricted to grade 2 or 3 PGD (non-PGD [n = 49], PGD [n = 24]).
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Moreover, this correlation, being primarily observed in the BAL and not in the plasma in subjects with 
PGD, suggests that activated complement products are concentrated to sites of  injury. Our data are con-
sistent with our previous findings in patients with other forms of  pulmonary inflammation in which the 
complement system is implicated, such as antibody-mediated rejection of  the lung (28). Additionally, 
our observations create a precedent for evaluating how intragraft MBL activation in the setting of  PGD 
could trigger chronic lung allograft dysfunction (CLAD). MBL localizes to the endothelium and base-
ment membrane during cold ischemia and obliterative bronchiolitis (45). On the other hand, low MBL 
levels in the airway have also been associated with CLAD, presumably through decreased efferocytosis 
(46). Thus, testing if  modulating the lectin pathway early after IRI reduces CLAD in experimental models 
of  LTx may potentially lead to a more targeted therapeutic approach in reducing PGD.
Our study has several limitations. First, there was a considerable difference in the overall inci-
dence of  PGD between the 2 cohorts, likely driven by differences in the patient populations at the 2 
centers. This has been previously reported in multicenter studies, wherein the range of  severe PGD 
ranged from 2%–27% (47). However, the relationship between complement activation and PGD held 
true when restricting the analysis to PGD occurring after 24 hours and those having grade 2 or 3 
PGD. Second, our sample size was small. A larger sample size of  patients within our selected date 
range could not be gathered due to limits in the availability of  concurrent plasma and BAL sam-
ples. Nevertheless, our sample size is consistent with other reported biomarker experiments in LTx 
(48–50). Third, we did not test for all the different MASPs, which would have provided additional 
specificity for the proteases that facilitate lectin pathway activation. Fourth, most studies using BAL 
bring into question whether the fluid is contaminated by blood/plasma, especially in the setting of  
an acute inflammatory process such as PGD. However, adjusting for permeability remains unreli-
able in human studies (51, 52). Additionally, the fact that there was no difference in these markers of  
activation in the plasma of  subjects with and without PGD would suggest that these differences are 
specific to the BAL, not simply a measure of  increased permeability. Fifth, there were inherent dif-
ferences in clinical practices at the 2 centers, including the variability in the volume of  fluid instilled 
into the lung as well as the return. However, in spite of  these differences, the relationship between 
local complement activation and PGD was still evident in both cohorts, providing further support 
for our overall findings. Finally, in accordance with other studies, we cannot state a definitive rela-
tionship between higher BAL markers of  complement activation and the increased PGD risk; rather, 
we can only describe the association between the 2 factors.
We conclude that there are marked differences between local and systemic complement activation 
in subjects who develop PGD. This difference was most evident in the local accumulation of  not only 
the classical and lectin pathway components, but also activation fragments of  the alternative pathway. 
MBL appears to be the most prominent marker of  lectin pathway activation in subjects with PGD. Addi-
tionally, elevated levels of  FCN-3 in the BAL highly correlate with markers of  complement activation. 
Future studies will involve exploring the relationship between lung-specific and systemic innate immune 
activation and local targeting of  the lectin pathway in experimental lung transplant models as a potential 
therapeutic avenue for reducing PGD incidence in patients with LTx.
Table 4. Correlation of lectin pathway components with markers of complement activation in bronchoalveolar lavage fluid within first 
24 hours of lung transplant (WUSM)
C4c TCC (sC5b-9)
Correlation P Correlation P
MBL 0.586 <0.001 0.637 <0.001
PTX3 0.361 0.022 0.318 0.045
FCN-1 0.078 0.632 0.109 0.505
FCN-2 0.250 0.120 0.309 0.052
FCN-3 0.679 < 0.001 0.703  <0.001
C4c – – 0.709  <0.001
FCN-1, ficolin-1; FCN-2, ficolin 2; FCN-3, ficolin-3; MBL, mannose-binding lectin; PTX3, long pentraxin 3; TCC, terminal complement complex. Correlation 
coefficient was determined using Spearman’s rho (n = 40)
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Methods
Study design, settings, and participants
This retrospective cohort study used BAL samples that had been independently collected at 2 centers, the 
University of  Pennsylvania and Washington University School of  Medicine (Figure 1).
Participants were enrolled at the University of  Pennsylvania as part of  the Prospective Registry of  
Outcomes in Patients Electing Lung Transplantation (PROPEL) (Penn cohort) (47). In this cohort, all BAL 
samples were collected from patients receiving a lung transplant between June 2013 and April 2017 at the 
Hospital of  the University of  Pennsylvania. At approximately 2 hours after allograft reperfusion, 20 mL 
PBS was instilled into the right middle lobe of  the lung, and a return of  5–10 mL was obtained, which was 
centrifuged, separated into supernatant aliquots and cell pellet suspensions, and then stored at –80°C until 
experimentation. Clinical data were collected for all patients.
BAL samples collected at Washington University School of  Medicine between July 2017 and January 
2019 (WUSM cohort) were used as a second independent cohort and for subsequent analyses. In this 
cohort, at 18–24 hours after allograft reperfusion, 100 mL PBS was instilled into the right middle lobe of  
Figure 4. PGD severity is associated with multiple pathways of complement activation. Multiplex assays done in the 
WUSM cohort (n = 73, Table 3 and Supplemental Table 3) were used to compare bronchoalveolar lavage (BAL) fluid levels 
of C1q, (A), C2 (B), and C4 (C) in subjects who developed PGD compared with those who did not. The presence of C4b, sug-
gestive of activation of both classical and lectin pathways, was compared in subjects with PGD and those without it (D). C2 
and C4 are involved in both the classical and lectin pathways of complement activation, while C1q is specific to the classical 
pathway, and MBL (E) is specific to the lectin pathway. Additionally, Ba, which is generated from factor B and represents 
activation of the alternative pathway, was measured (F). Rank sum tests of comparison (Mann-Whitney U test).
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the lung, centrifuged, separated into aliquots, and stored. The processing of  the samples in the laboratory 
was similar to that at the University of  Pennsylvania. Blood samples were collected from the same recip-
ients at the same time the BAL specimens were obtained. These were transported on ice, centrifuged to 
collect plasma, and stored at –80°C.
Outcome definition
PGD is defined as a syndrome of  acute lung injury occurring early after LTx, graded on the basis of  
pulmonary edema on chest radiographs and the degree of  hypoxemia, and measured by the PaO2/
FiO2 ratio. PaO2 is the partial pressure of  arterial oxygen, and FiO2 is the fraction of  inspired oxygen 
(Supplemental Table 1) (1). In the Penn cohort, the primary outcome considered was grade 3 PGD 
occurring within the first 48–72 hours after LTx, as defined by the International Society for Heart and 
Lung Transplant guidelines (2). Because of  institutional differences in recipient characteristics between 
the Penn and WUSM cohorts, including the difference between the number of  transplants done on 
ECLS, the number of  grade 2 or 3 PGD cases was fewer in the WUSM cohort. Because there were 
fewer cases of  grade 2 or 3 PGD in the WUSM cohort, an alternative definition of  “any grade of  PGD 
(any PGD)” was used for the analysis in the WUSM cohort. In this scenario, patients with any grade 
of  PGD (grades 1–3) were considered as having PGD, and a sensitivity analysis was conducted after 
excluding those who developed PGD before 24 hours. Additionally, a subgroup analysis was done con-
sidering the smaller number of  subjects in the WUSM cohort who had grade 2 or 3 PGD. PGD scoring 
was independently done in a blinded manner by members of  the transplant team (47).
Protein concentration measurement
Participants were screened for complement activation in the BAL using the sC5b-9 assay (BD OptEIA 
Human C5b-9 ELISA set) and the sC4d assay (Quidel MicroVue ELISA). Individual complement analytes 
were evaluated using a modified MILLIPLEX MAP Human Complement Panel 1 and 2 (MilliporeSigma). 
Lectin pathway analytes were measured in both plasma and BAL. All BAL or plasma aliquots that were 
used had been through no more than 1 freeze-thaw cycle. Laboratory personnel were blinded to PGD status.
Figure 5. Local markers of lectin pathway activation distinguish subjects with PGD. Levels of mannose-binding lectin 
(MBL) in the bronchoalveolar lavage (BAL) highly correlated with markers of complement activation in the BAL (soluble 
terminal complement complex [TCC]) in the WUSM cohort (A, n = 40). Using a different assay than in Figure 4 (n = 73), BAL 
MBL levels were higher in subjects who developed PGD compared with the levels in subjects without PGD (C), and this held 
true in those who developed PGD at or after 24 hours (D). The levels of ficolin-3 (FCN3; B) also highly correlated with BAL TCC 
(n = 40). r represents Spearman’s rho coefficient. The axes were expressed in a logarithmic scale for purposes of graphical 
representation. Rank sum tests of comparison (Mann-Whitney U test).
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Measurements of different complement components
sC5b-9 assay. Participants were screened for complement activation in the BAL using the sC5b-9 assay 
(BD OptEIA Human C5b-9 ELISA set) (53, 54). Per the manufacturer’s instructions, purified native 
human C3, C4, C5, C6, C7, C8, and C9 have been tested in the BD OptEIA assay at ≥5 mg/mL, and no 
cross-reactivity (value ≥470 pg/mL) was identified.
sC4d assay. sC4d was detected in the BAL using a highly specific C4d assay (Quidel MicroVue ELISA), 
which has previously been used to detect C4d in BAL fluid. (55, 56)
Individual complement analytes using MILLIPLEX assay. Individual complement analytes were evaluated 
using a modified MILLIPLEX MAP Human Complement Panel 1 and 2 (MilliporeSigma, Supplemental 
Table 3) based on the Luminex xMAP technology, a bead-based multiplex assay. Specifically, we used the 
MILLIPLEX MAP Human Complement Panel 1 (HCMP1MAG) to simultaneously quantify the follow-
ing analytes in the BAL: complement C2, complement C4b, complement C5, complement C5a, comple-
ment C9, adipsin (complement factor D), and MBL. Of  note, this assay is specific for C4b and does not 
cross-react with C4d (per communication with manufacturer). The C5 measurements are distinct from 
C5a, as the intact factors are designed such as they would not detect individual fragments based on their 
capture and detection antibodies.
Similarly, we used the MILLIPLEX MAP Human Complement Panel 2 (HCMP2MAG) to simultane-
ously quantify the following analytes in the BAL: complement C1q, complement C3, complement C3b/iC3b, 
complement C4, and complement factor B. Of note, the assay for C3b/iC3b detects both C3b and iC3b (per 
communication with manufacturer). The factor B assay does not detect either fragments Bb or Ba.
Lectin pathway analytes. The following lectin pathway pattern recognition molecules were measured in both 
plasma and BAL in duplicate: MBL, PTX3, FCN-1, FCN-2, and FCN-3 were quantified in specific sandwich 
ELISAs with monoclonal antibodies for each marker developed in the Laboratory of Molecular Medicine, 
Rigshospitalet, according to previously described procedures (57–61). All assays were optimized for automated 
analysis in a 384-well format on the Biomek FX robotic system (Beckman Coulter) (62). Alternative assays for 
C4 activation, i.e., C4c and sC5b-9 (TCC) were measured in ELISAs based on monoclonal antibodies against 
neoepitopes on the C4c fragment and C9 not exposed on the native molecules as described previously (63, 64).
Alternative pathway analytes. Ba was measured in duplicate in the WUSM cohort using the Microvue 
Complement Ba fragment EIA kit (A033, Quidel Inc.).
PTX3 assay. BAL concentrations of  PTX3 were measured in duplicate in the Penn cohort using com-
mercially available sandwich ELISAs (PTX3, Quantikine ELISA) as described previously (10, 11).
Statistics
PGD associations with BAL levels of  complement proteins were evaluated using rank sum tests. Given the 
sample size, we were stricter in our hypothesis testing and used nonparametric tests for comparison (e.g., 
assuming the data did not follow a normal distribution). Specifically, 2 independent groups were compared 
using the Mann-Whitney U test, and multiple group comparisons were done using nonparametric test for 
trends. For statistical analysis, the analysis corrected for multiple comparisons when comparing more than 2 
groups. All statistical tests for comparison were 2 sided, and P < 0.05 was considered significant. In all figures, 
Figure 6. Local PTX3 moderately correlated with markers of complement activation. Levels of long pentraxin 
3 (PTX3) in the bronchoalveolar lavage (BAL) only had a modest correlation with markers of complement activa-
tion in the BAL (C4d) in the Penn cohort (A, n = 113). This correlation held true in the second independent cohort 
(WUSM, n = 40) for the terminal complement complex (TCC; B) and was also true for C4c (C). r represents Spear-
man’s rho coefficient. The axes were expressed in a logarithmic scale for purposes of graphical representation.
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the error bars are defined such that data represent median with IQR. The correlation between complement 
activation proteins and individual analytes was assessed using Spearman’s correlation. Statistical analysis was 
performed using STATA 13.1 software (STATA Corp.); GraphPad Prism 8 was used for generating graphs.
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